tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

REPL Stock Latest News

REPL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Pre-EarningsREPL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12d ago
REPL
Replimune price target raised to $17 from $14 at JPMorgan
PremiumThe Fly
Replimune price target raised to $17 from $14 at JPMorgan
2M ago
REPL
Replimune presents primary analysis data from IGNYTE clinical trial
PremiumThe Fly
Replimune presents primary analysis data from IGNYTE clinical trial
2M ago
REPL
Replimune completes pre-BLA meeting with FDA for RP1
PremiumThe Fly
Replimune completes pre-BLA meeting with FDA for RP1
2M ago
REPL
Replimune appoints Balachandran to board of directors
PremiumThe Fly
Replimune appoints Balachandran to board of directors
2M ago
REPL
Replimune initiated with a Buy at Roth MKM
PremiumThe FlyReplimune initiated with a Buy at Roth MKM
2M ago
REPL
Replimune announces first patient dosed in IGNYTE-3 trial
Premium
The Fly
Replimune announces first patient dosed in IGNYTE-3 trial
3M ago
REPL
Replimune Group price target lowered to $14 from $17 at JPMorgan
Premium
The Fly
Replimune Group price target lowered to $14 from $17 at JPMorgan
3M ago
REPL
Replimune Group initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Replimune Group initiated with a Buy at Rodman & Renshaw
3M ago
REPL
Replimune Group files to sell 11.34M shares of common stock for holders
PremiumThe Fly
Replimune Group files to sell 11.34M shares of common stock for holders
3M ago
REPL
Replimune Group sees cash runway into 2H26
PremiumThe Fly
Replimune Group sees cash runway into 2H26
3M ago
REPL
Replimune Group reports Q1 EPS (78c), consensus (85c)
PremiumThe Fly
Replimune Group reports Q1 EPS (78c), consensus (85c)
3M ago
REPL
Replimune Group Secures Funding for Cancer Treatment Expansion
PremiumCompany AnnouncementsReplimune Group Secures Funding for Cancer Treatment Expansion
5M ago
8K
REPL
Replimune Group to sell 5.67M shares at $8.82 in private placement
Premium
The Fly
Replimune Group to sell 5.67M shares at $8.82 in private placement
5M ago
REPL
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
BCDA
GERN
Replimune Group price target raised to $17 from $12 at H.C. Wainwright
PremiumThe Fly
Replimune Group price target raised to $17 from $12 at H.C. Wainwright
5M ago
REPL
Replimune Group price target raised to $17 from $13 at Barclays
PremiumThe Fly
Replimune Group price target raised to $17 from $13 at Barclays
5M ago
REPL
Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes
PremiumCompany Announcements
Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes
5M ago
8K
REPL
Replimune Group announces topline results from primary analysis of IGNYTE trial
PremiumThe Fly
Replimune Group announces topline results from primary analysis of IGNYTE trial
5M ago
REPL
Replimune Group presents positive data from RP1 and RP2 programs at ASCO
PremiumThe FlyReplimune Group presents positive data from RP1 and RP2 programs at ASCO
5M ago
REPL
Replimune Group expects cash to fund operations into 2Q26
Premium
The Fly
Replimune Group expects cash to fund operations into 2Q26
6M ago
REPL
Replimune Group reports 2024 EPS ($3.24), consensus ($3.27)
Premium
The Fly
Replimune Group reports 2024 EPS ($3.24), consensus ($3.27)
6M ago
REPL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >